Patents by Inventor Melissa Damschroder

Melissa Damschroder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150023966
    Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.
    Type: Application
    Filed: November 6, 2012
    Publication date: January 22, 2015
    Inventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, SAndrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Godfrey Rainney, Cuihua GAO
  • Patent number: 8883992
    Abstract: Isolated nucleic acids encoding anti-CD19 mouse monoclonal antibodies are described herein. Also described are expression vectors, host cells and a method of producing anti-CD19 antibodies.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: November 11, 2014
    Assignee: Medimmune, LLC
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Publication number: 20140171623
    Abstract: The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., Fc?Rs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc?R and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
    Type: Application
    Filed: February 17, 2014
    Publication date: June 19, 2014
    Applicant: MedImmune, LLC
    Inventors: William Dall'Acqua, Herren Wu, Melissa Damschroder, Jose Casas-Finet
  • Patent number: 8697396
    Abstract: The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., Fc?Rs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc?R and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
    Type: Grant
    Filed: July 25, 2011
    Date of Patent: April 15, 2014
    Assignee: MedImmune, LLC
    Inventors: William Dall'Acqua, Herren Wu, Melissa Damschroder, Jose Casas-Finet
  • Publication number: 20140072577
    Abstract: Herein provided are compositions, methods of manufacture and methods of use pertaining to anti-alpha toxin antibodies and fragments.
    Type: Application
    Filed: February 7, 2012
    Publication date: March 13, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: Bret Sellman, Christine Tkaczyk, Lei Hua, Partha Chowdhury, Reena Varkey, Melissa Damschroder, Li Peng, Vaheh Oganesyan, Jamese Johnson Hilliard
  • Patent number: 8323653
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: December 4, 2012
    Assignee: MedImmune, LLC
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Publication number: 20120046450
    Abstract: The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., Fc?Rs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc?R and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
    Type: Application
    Filed: July 25, 2011
    Publication date: February 23, 2012
    Applicant: MedImmune, LLC
    Inventors: William Dall'Acqua, Herren Wu, Melissa Damschroder, Jose Casas-Finet
  • Patent number: 8008443
    Abstract: The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., Fc?Rs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc?R and/or CIq. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: August 30, 2011
    Assignee: MedImmune, LLC
    Inventors: William Dall'Acqua, Herren Wu, Melissa Damschroder, Jose Casa-Finet
  • Publication number: 20110077383
    Abstract: The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which improves stability and/or alters the binding of Fc to one or more metal ion and/or one or more Fc ligand (e.g., Fc?Rs) and/or modulates effector function. More specifically, this invention provides Fc variants that are less susceptible to metal ion-mediated cleavage and/or have modified binding affinity to one or more Fc?R and/or C1q. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. Furthermore, the modified hinge of the Fc variants retains a similar flexibility to the wild type hinge. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
    Type: Application
    Filed: July 2, 2008
    Publication date: March 31, 2011
    Applicant: MEDIMMUNE, LLC
    Inventors: William Dall'Acqua, Herren Wu, Melissa Damschroder, Jose Casas-Finet, Raul Cachau
  • Publication number: 20100216975
    Abstract: The present invention relates to methods of reengineering or reshaping antibodies to reduce the immunogenicity of the antibodies, while maintaining the immunospecificity of the antibodies for an antigen. In particular, the present invention provides methods of producing antibodies immunospecific for an antigen by synthesizing a combinatorial library comprising complementarity determining regions (CDRs) from a donor antibody fused in frame to framework regions from a sub-bank of framework regions. The invention also provides method of producing improved humanized antibodies. The present invention also provides antibodies produced by the methods of the invention.
    Type: Application
    Filed: February 1, 2010
    Publication date: August 26, 2010
    Applicant: MEDIMMUNE, LLC
    Inventors: Herren WU, William Dall-Acqua, Melissa DAMSCHRODER
  • Publication number: 20100145028
    Abstract: The present invention relates to a reliable, reproducible method for improving the producibility of an antibody. More specifically, this invention provides a method for modifying the heavy chain of an antibody to improve its producibility in eukaryotic cells. Additionally, the method of the invention may improve both antibody producibility and one or more antigen binding characteristics. The invention further provides modified antibodies which are better produced and which have either no change in their antigen binding characteristics or exhibit improved antigen binding characteristics.
    Type: Application
    Filed: February 16, 2010
    Publication date: June 10, 2010
    Applicant: MEDIMMUNE, LLC
    Inventors: William DALL'ACQUA, Herren WU, Melissa DAMSCHRODER
  • Publication number: 20090297514
    Abstract: The present invention provides methods of re-engineering or re-shaping an antibody from a first species, wherein the re-engineered or re-shaped antibody does not elicit undesired immune response in a second species, and the re-engineered or re-shaped antibody retains substantially the same antigen binding-ability of the antibody from the first species. In accordance with the present invention, a combinatorial library comprising the CDRs of the antibody from the first species fused in frame with framework regions derived from a second species can be constructed and screened for the desired modified antibody. In particular, the present invention provides methods utilizing low homology acceptor antibody frameworks for efficiently humanizing an antibody or a fragment thereof. The present invention also provides antibodies produced by the methods of the invention.
    Type: Application
    Filed: May 8, 2009
    Publication date: December 3, 2009
    Applicant: MEDIMMUNE, LLC
    Inventors: Herren WU, William DALL-ACQUA, Melissa DAMSCHRODER
  • Publication number: 20090221803
    Abstract: The present invention relates to novel molecules (Fc variants) comprising at least one antigen binding region and an Fc region that further comprises a modified hinge which alters the binding of Fc to one or more Fc ligand (e.g., Fc?Rs) and/or modulates effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc?R and/or CIq. Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants particularly for therapeutic purposes.
    Type: Application
    Filed: April 25, 2006
    Publication date: September 3, 2009
    Applicant: MEDIMMUNE, INC.
    Inventors: William Dall'Acqua, Herren Wu, Melissa Damschroder, Jose Casas-Finet
  • Publication number: 20090220527
    Abstract: The present invention relates to antibodies with increased affinities that preferentially bind an EphA2 epitope exposed on cancer cells but not non-cancer cells. The present invention further relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The invention also provides pharmaceutical compositions comprising one or more EphA2 antibodies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
    Type: Application
    Filed: December 20, 2006
    Publication date: September 3, 2009
    Applicant: MEDLMMUNE, LLC
    Inventors: Melissa Damschroder, William Dall'Acqua, Herren Wu, Michael Kinch
  • Publication number: 20080138336
    Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
    Type: Application
    Filed: September 7, 2007
    Publication date: June 12, 2008
    Applicant: Medlmmune, Inc.
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Publication number: 20060228350
    Abstract: The present invention relates to methods of reengineering or reshaping antibodies to reduce the immunogenicity of the antibodies, while maintaining the immunospecificity of the antibodies for an antigen. In particular, the present invention provides methods of producing antibodies immunospecific for an antigen by synthesizing a combinatorial library comprising complementarity determining regions (CDRs) from a donor antibody fused in frame to framework regions from a sub-bank of framework regions. The invention also provides method of producing improved humanized antibodies. The present invention also provides antibodies produced by the methods of the invention.
    Type: Application
    Filed: March 17, 2006
    Publication date: October 12, 2006
    Applicant: MEDIMMUNE, INC.
    Inventors: Herren Wu, William Dall-Acqua, Melissa Damschroder
  • Publication number: 20060121042
    Abstract: The present invention relates to methods and compositions designed for the treatment, management, prevention and/or amelioration of various disorders associated with aberrant expression and/or activity of one or more Eph receptor tyrosine kinase family members and/or one or more Eph receptor ligands, particularly the Ephrins. In particular, the invention provides methods for the treatment, management, prevention and/or amelioration of a disorder associated with aberrant expression and/or activity(ies) of one or more Eph receptors and/or one or more Ephrins, the method comprising administering to a subject in need thereof an effective amount of one or more Eph/Ephrin Modulators. The present invention further relates to methods of modulating antibody specificity by tailoring the affinity to cognate antigens.
    Type: Application
    Filed: October 27, 2005
    Publication date: June 8, 2006
    Applicant: MEDIMMUNE, INC.
    Inventors: William Dall'Acqua, Melissa Damschroder, Michael Kinch, Kelly Carles-Kinch
  • Publication number: 20060019342
    Abstract: The present invention relates to a reliable, reproducible method for improving the producibility of an antibody. More specifically, this invention provides a method for modifying the heavy chain of an antibody to improve its producibility in eukaryotic cells. Additionally, the method of the invention may improve both antibody producibility and one or more antigen binding characteristics. The invention further provides modified antibodies which are better produced and which have either no change in their antigen binding characteristics or exhibit improved antigen binding characteristics.
    Type: Application
    Filed: June 24, 2005
    Publication date: January 26, 2006
    Applicant: MEDIMMUNE, INC.
    Inventors: William Dall'Acqua, Herren Wu, Melissa Damschroder
  • Publication number: 20050181479
    Abstract: The present invention relates to recombinant polynucleotides, expression vectors and methods for the production of multimeric proteins. The vectors and methods are useful for the production of multimeric protein and are unique in that they utilize a minimal number of signal sequences. More specifically, the present invention provides recombinant polynucleotide molecules and expression vectors comprising a promoter region operably linked to a transcription unit. The transcription unit is characterized by at least two DNA sequences encoding distinct polypeptides wherein at least one but not all DNA sequences further encodes a signal sequence operably linked to the DNA sequence encoding a polypeptide. The invention further provides methods of producing a multimeric protein using the expression vectors of the present invention.
    Type: Application
    Filed: March 4, 2005
    Publication date: August 18, 2005
    Applicant: MEDIMMUNE, INC.
    Inventors: William Dall'Acqua, Herren Wu, Melissa Damschroder
  • Publication number: 20050048617
    Abstract: The present invention relates to methods of reengineering or reshaping antibodies to reduce the immunogenicity of the antibodies, while maintaining the immunospecificity of the antibodies for an antigen. In particular, the present invention provides methods of producing antibodies immunospecific for an antigen by synthesizing a combinatorial library comprising complementarity determining regions (CDRs) from a donor antibody fused in frame to framework regions from a sub-bank of framework regions. The present invention also provides antibodies produced by the methods of the invention.
    Type: Application
    Filed: August 18, 2004
    Publication date: March 3, 2005
    Applicant: MEDIMMUNE, INC.
    Inventors: Herren Wu, William Dall-Acqua, Melissa Damschroder